发明授权
US09187441B2 p53-Mdm2 antagonists 有权
p53-Mdm2拮抗剂

p53-Mdm2 antagonists
摘要:
Novel p53-Mdm2 antogonists that conform to Formula I or to Formula II: where the prescribed substituent groups are defined, are useful in treating or preventing cancer. In particular, the compounds and their pharmaceutical compositions are useful for treating relapsed/refractory acute myeloid and lymphoid leukemia and refractory chronic lymphocytic leukemia/small cell lymphocytic lymphomas.
公开/授权文献
信息查询
0/0